Pediatric Pharmacokinetics. Human Development and Drug Disposition.

Pediatric Clinics of North America

Volumn 59, Issue 5, 2012, Pages 1001-1016

  Funk, Ryan S ^a   Brown, Jacob T ^a   Abdel Rahman, Susan M ^a,b  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Absorption; Development; Distribution; Excretion; Metabolism; Pediatric; Pharmacokinetic; Transport

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A1; IBUPROFEN; PARACETAMOL; SULFOTRANSFERASE 1A1; WARFARIN;

BODY COMPOSITION; CHILD DEVELOPMENT; DEVELOPMENTAL BIOLOGY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; HUMAN; REVIEW; STOMACH EMPTYING;

CHILD; HUMANS; PEDIATRICS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 84867040966     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2012.07.003     Document Type: Review

References (93)

1. Abdel-Rahman S.M., Kauffman R.E. The integration of pharmacokinetics and pharmacodynamics: understanding dose-response. Annu Rev Pharmacol Toxicol 2004, 44:111-136.
2. Agunod M., Yamaguchi N., Lopez R., et al. Correlative study of hydrochloric acid, pepsin, and intrinsic factor secretion in newborns and infants. Am J Dig Dis 1969, 14(6):400-414.
3. Hogben C.A., Schanker L.S., Tocco D.J., et al. Absorption of drugs from the stomach. II. The human. J Pharmacol Exp Ther 1957, 120(4):540-545.
4. Heimann G. Enteral absorption and bioavailability in children in relation to age. Eur J Clin Pharmacol 1980, 18(1):43-50.
5. Milsap R.L., Jusko W.J. Pharmacokinetics in the infant. Environ Health Perspect 1994, 11(Suppl 102):107-110.
6. Huang N.N., High R.H. Comparison of serum levels following the administration of oral and parenteral preparations of penicillin to infants and children of various age groups. J Pediatr 1953, 42(6):657-658.
7. Parrott N., Lukacova V., Fraczkiewicz G., et al. Predicting pharmacokinetics of drugs using physiologically based modeling-application to food effects. AAPS J 2009, 11(1):45-53.
8. Poley J.R., Dower J.C., Owen C.A., et al. Bile acids in infants and children. J Lab Clin Med 1964, 63:838-846.
9. Suchy F.J., Balistreri W.F., Heubi J.E., et al. Physiologic cholestasis: elevation of the primary serum bile acid concentrations in normal infants. Gastroenterology 1981, 80(5 Pt 1):1037-1041.
10. Abdel-Rahman S.M., Kearns G.L. Single oral dose escalation pharmacokinetics of pleconaril (VP 63843) capsules in adults. J Clin Pharmacol 1999, 39(6):613-618.
11. Kearns G.L., Bradley J.S., Jacobs R.F., et al. Single dose pharmacokinetics of pleconaril in neonates. Pediatric Pharmacology Research Unit Network. Pediatr Infect Dis J 2000, 19(9):833-839.
12. Gupta M., Brans Y.W. Gastric retention in neonates. Pediatrics 1978, 62(1):26-29.
13. Dressman J.B., Bass P., Ritschel W.A., et al. Gastrointestinal parameters that influence oral medications. J Pharm Sci 1993, 82(9):857-872.
14. Berseth C.L. Gestational evolution of small intestine motility in preterm and term infants. J Pediatr 1989, 115(4):646-651.
15. Kearns G.L., Robinson P.K., Wilson J.T., et al. Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. Clin Pharmacol Ther 2003, 74(4):312-325.
16. Stahlberg M.R., Hietanen E., Maki M. Mucosal biotransformation rates in the small intestine of children. Gut 1988, 29(8):1058-1063.
17. Johnson T.N., Tanner M.S., Taylor C.J., et al. Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. Br J Clin Pharmacol 2001, 51(5):451-460.
18. Gibbs J.P., Liacouras C.A., Baldassano R.N., et al. Up-regulation of glutathione S-transferase activity in enterocytes of young children. Drug Metab Dispos 1999, 27(12):1466-1469.
19. Pacha J. Development of intestinal transport function in mammals. Physiol Rev 2000, 80(4):1633-1667.
20. Gladtke E., Rind H. Iron therapy during childhood. Ger Med Mon 1966, 11(11):438-442.
21. Garrick M.D. Human iron transporters. Genes Nutr 2011, 6(1):45-54.
22. Fakhoury M., Litalien C., Medard Y., et al. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab Dispos 2005, 33(11):1603-1607.
23. Abdel-Rahman S.M., Johnson F.K., Gauthier-Dubois G., et al. The bioequivalence of nizatidine (Axid) in two extemporaneously and one commercially prepared oral liquid formulations compared with capsule. J Clin Pharmacol 2003, 43(2):148-153.
24. Abdel-Rahman S.M., Johnson F.K., Connor J.D., et al. Developmental pharmacokinetics and pharmacodynamics of nizatidine. J Pediatr Gastroenterol Nutr 2004, 38(4):442-451.
25. Fanta S., Niemi M., Jonsson S., et al. Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet Genomics 2008, 18(2):77-90.
26. Morimoto K., Kishimura K., Nagami T., et al. Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers. J Pharm Sci 2011, 100(9):3854-3861.
27. Di Lorenzo C., Flores A.F., Hyman P.E. Age-related changes in colon motility. J Pediatr 1995, 127(4):593-596.
28. van Lingen R.A., Deinum J.T., Quak J.M., et al. Pharmacokinetics and metabolism of rectally administered paracetamol in preterm neonates. Arch Dis Child Fetal Neonatal Ed 1999, 80(1):F59-F63.
29. Okah F.A., Wickett R.R., Pickens W.L., et al. Surface electrical capacitance as a noninvasive bedside measure of epidermal barrier maturation in the newborn infant. Pediatrics 1995, 96(4 Pt 1):688-692.
30. Fluhr J.W., Pfisterer S., Gloor M. Direct comparison of skin physiology in children and adults with bioengineering methods. Pediatr Dermatol 2000, 17(6):436-439.
31. West D.P., Worobec S., Solomon L.M. Pharmacology and toxicology of infant skin. J Invest Dermatol 1981, 76(3):147-150.
32. Carry M.R., Ringel S.P., Starcevich J.M. Distribution of capillaries in normal and diseased human skeletal muscle. Muscle Nerve 1986, 9(5):445-454.
33. Sheng K.T., Huang N.N., Promadhattavedi V. Serum concentrations of cephalothin in infants and children and placental transmission of the antibiotic. Antimicrob Agents Chemother (Bethesda) 1964, 10:200-206.
34. Kafetzis D.A., Sinaniotis C.A., Papadatos C.J., et al. Pharmacokinetics of amikacin in infants and pre-school children. Acta Paediatr Scand 1979, 68(3):419-422.
35. Friis-Hansen B. Water distribution in the foetus and newborn infant. Acta Paediatr Scand 1983, 305:7-11.
36. Siber G.R., Echeverria P., Smith A.L., et al. Pharmacokinetics of gentamicin in children and adults. J Infect Dis 1975, 132(6):637-651.
37. Kearns G.L., Abdel-Rahman S.M., Blumer J.L., et al. Single dose pharmacokinetics of linezolid in infants and children. Pediatr Infect Dis J 2000, 19(12):1178-1184.
38. Noone P., Parsons T.M., Pattison J.R., et al. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J 1974, 1(5906):477-481.
39. Moore R.D., Smith C.R., Lietman P.S. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984, 149(3):443-448.
40. Kurz H., Fichtl B. Binding of drugs to tissues. Drug Metab Rev 1983, 14(3):467-510.
41. MacIntyre A.C., Cutler D.J. The potential role of lysosomes in tissue distribution of weak bases. Biopharm Drug Dispos 1988, 9(6):513-526.
42. Yokogawa K., Ishizaki J., Ohkuma S., et al. Influence of lipophilicity and lysosomal accumulation on tissue distribution kinetics of basic drugs: a physiologically based pharmacokinetic model. Methods Find Exp Clin Pharmacol 2002, 24(2):81-93.
43. Haddad S., Restieri C., Krishnan K. Characterization of age-related changes in body weight and organ weights from birth to adolescence in humans. J Toxicol Environ Health A 2001, 64(6):453-464.
44. Windorfer A., Kuenzer W., Urbanek R. The influence of age on the activity of acetylsalicylic acid-esterase and protein-salicylate binding. Eur J Clin Pharmacol 1974, 7(3):227-231.
45. Nau H., Luck W., Kuhnz W. Decreased serum protein binding of diazepam and its major metabolite in the neonate during the first postnatal week relate to increased free fatty acid levels. Br J Clin Pharmacol 1984, 17(1):92-98.
46. Rane A., Lunde P.K., Jalling B., et al. Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants. J Pediatr 1971, 78(5):877-882.
47. Kanakoudi F., Drossou V., Tzimouli V., et al. Serum concentrations of 10 acute-phase proteins in healthy term and preterm infants from birth to age 6 months. Clin Chem 1995, 41(4):605-608.
48. Kingston H.G., Kendrick A., Sommer K.M., et al. Binding of thiopental in neonatal serum. Anesthesiology 1990, 72(3):428-431.
49. Meistelman C., Benhamou D., Barre J., et al. Effects of age on plasma protein binding of sufentanil. Anesthesiology 1990, 72(3):470-473.
50. Daood M., Tsai C., Ahdab-Barmada M., et al. ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS. Neuropediatrics 2008, 39(4):211-218.
51. Lacroix D., Sonnier M., Moncion A., et al. Expression of CYP3A in the human liver-evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997, 247(2):625-634.
52. Stevens J.C., Hines R.N., Gu C., et al. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 2003, 307(2):573-582.
53. Maya M.T., Domingos C.R., Guerreiro M.T., et al. Comparative bioavailability of two immediate release tablets of cisapride in healthy volunteers. Eur J Drug Metab Pharmacokinet 1998, 23(3):377-381.
54. Mukherjee A., Dombi T., Wittke B., et al. Population pharmacokinetics of sildenafil in term neonates: evidence of rapid maturation of metabolic clearance in the early postnatal period. Clin Pharmacol Ther 2009, 85(1):56-63.
55. Blake M.J., Gaedigk A., Pearce R.E., et al. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther 2007, 81(4):510-516.
56. Koukouritaki S.B., Manro J.R., Marsh S.A., et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 2004, 308(3):965-974.
57. Bourgeois B.F., Dodson W.E. Phenytoin elimination in newborns. Neurology 1983, 33(2):173-178.
58. Whelan H.T., Hendeles L., Haberkern C.M., et al. High intravenous phenytoin dosage requirement in a newborn infant. Neurology 1983, 33(1):106-108.
59. Jacqz-Aigrain E., Bellaich M., Faure C., et al. Pharmacokinetics of intravenous omeprazole in children. Eur J Clin Pharmacol 1994, 47(2):181-185.
60. Faure C., Michaud L., Shaghaghi E.K., et al. Intravenous omeprazole in children: pharmacokinetics and effect on 24-hour intragastric pH. J Pediatr Gastroenterol Nutr 2001, 33(2):144-148.
61. Nowak-Gottl U., Dietrich K., Schaffranek D., et al. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood 2010, 116(26):6101-6105.
62. Vieira I., Sonnier M., Cresteil T. Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. Eur J Biochem 1996, 238(2):476-483.
63. Sonnier M., Cresteil T. Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem 1998, 251(3):893-898.
64. de Wildt S.N., Kearns G.L., Leeder J.S., et al. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet 1999, 36(6):439-452.
65. Strassburg C.P., Strassburg A., Kneip S., et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 2002, 50(2):259-265.
66. Scott C.S., Riggs K.W., Ling E.W., et al. Morphine pharmacokinetics and pain assessment in premature newborns. J Pediatr 1999, 135(4):423-429.
67. Duanmu Z., Weckle A., Koukouritaki S.B., et al. Developmental expression of aryl, estrogen, and hydroxysteroid sulfotransferases in pre- and postnatal human liver. J Pharmacol Exp Ther 2006, 316(3):1310-1317.
68. Strange R.C., Davis B.A., Faulder C.G., et al. The human glutathione S-transferases: developmental aspects of the GST1, GST2, and GST3 loci. Biochem Genet 1985, 23(11-12):1011-1028.
69. Miller R.P., Roberts R.J., Fischer L.J. Acetaminophen elimination kinetics in neonates, children, and adults. Clin Pharmacol Ther 1976, 19(3):284-294.
70. Allegaert K., Van der Marel C.D., Debeer A., et al. Pharmacokinetics of single dose intravenous propacetamol in neonates: effect of gestational age. Arch Dis Child Fetal Neonatal Ed 2004, 89(1):F25-F28.
71. Bjorkman S., Oh M., Spotts G., et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 2012, 119(2):612-618.
72. Rosenbaum M., Gertner J.M. Metabolic clearance rates of synthetic human growth hormone in children, adult women, and adult men. J Clin Endocrinol Metab 1989, 69(4):820-824.
73. Kearns G.L., Kemp S.F., Frindik J.P. Single and multiple dose pharmacokinetics of methionyl growth hormone in children with idiopathic growth hormone deficiency. J Clin Endocrinol Metab 1991, 72(5):1148-1156.
74. Brown M.S., Jones M.A., Ohls R.K., et al. Single-dose pharmacokinetics of recombinant human erythropoietin in preterm infants after intravenous and subcutaneous administration. J Pediatr 1993, 122(4):655-657.
75. Mortensen H.B., Lindholm A., Olsen B.S., et al. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur J Pediatr 2000, 159(7):483-488.
76. Danne T., Lupke K., Walte K., et al. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care 2003, 26(11):3087-3092.
77. Danne T., Becker R.H., Heise T., et al. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 2005, 28(9):2100-2105.
78. McCrory W.M. Embryonic development and prenatal maturation of the kidney. Pediatric kidney disease 1978, 3-25. Little, Brown and Company, Boston. C.M. Edelman (Ed.).
79. Spitzer A. Renal physiology and functional development. Pediatric kidney disease 1978, 25-128. Little, Brown and Company, Boston. C.M. Edelmann (Ed.).
80. Children are different: developmental physiology 1978, Ross Labs, Columbus (OH). 2nd edition. T.R. John, W.M. Moore, J.E. Jeffries (Eds.).
81. Hayton W.L. Maturation and growth of renal function: dosing renally cleared drugs in children. AAPS PharmSci 2000, 2(1):E3.
82. Chen N., Aleksa K., Woodland C., et al. Ontogeny of drug elimination by the human kidney. Pediatr Nephrol 2006, 21(2):160-168.
83. Matzke G.R., McGory R.W., Halstenson C.E., et al. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrobial Agents Chemother 1984, 25(4):433-437.
84. Schaad U.B., McCracken G.H., Nelson J.D. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 1980, 96(1):119-126.
85. Saxen H., Hoppu K., Pohjavuori M. Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin Pharmacol Ther 1993, 54(3):269-277.
86. Buist S.C., Cherrington N.J., Choudhuri S., et al. Gender-specific and developmental influences on the expression of rat organic anion transporters. J Pharmacol Exp Ther 2002, 301(1):145-151.
87. Slitt A.L., Cherrington N.J., Hartley D.P., et al. Tissue distribution and renal developmental changes in rat organic cation transporter mRNA levels. Drug Metab Dispos 2002, 30(2):212-219.
88. Rosati A., Maniori S., Decorti G., et al. Physiological regulation of P-glycoprotein, MRP1, MRP2 and cytochrome P450 3A2 during rat ontogeny. Dev Growth Differ 2003, 45(4):377-387.
89. Maher J.M., Slitt A.L., Cherrington N.J., et al. Tissue distribution and hepatic and renal ontogeny of the multidrug resistance-associated protein (Mrp) family in mice. Drug Metab Dispos 2005, 33(7):947-955.
90. Alnouti Y., Petrick J.S., Klaassen C.D. Tissue distribution and ontogeny of organic cation transporters in mice. Drug Metab Dispos 2006, 34(3):477-482.
91. Rollins D.E., Klaassen C.D. Biliary excretion of drugs in man. Clin Pharmacokinet 1979, 4(5):368-379.
92. Rosenfeld W.N., Evans H.E., Batheja R., et al. Pharmacokinetics of cefoperazone in full-term and premature neonates. Antimicrobial Agents Chemother 1983, 23(6):866-869.
93. Hayton W.L., Stoeckel K. Age-associated changes in ceftriaxone pharmacokinetics. Clin Pharmacokinet 1986, 11(1):76-86.